Table 1.
Demographics
| Characteristic | Preintervention (n = 133) | Postintervention (n = 163) | Overall (n = 296) |
|---|---|---|---|
| Age, years | |||
| Mean | 62 | 63 | 63 |
| Median | 62 | 64 | 63 |
| Range | 26–88 | 25–96 | 25–96 |
| Sex, n (%) | |||
| Female | 64 (48) | 82 (50) | 146 (49) |
| Male | 69 (52) | 81 (50) | 150 (51) |
| Race | |||
| White | 83 (62) | 101 (62) | 184 (62) |
| Black | 46 (35) | 53 (33) | 99 (33) |
| Other | 4(3) | 9 (5) | 13 (4) |
| Insurance, n (%) | |||
| Medicare | 63 (47) | 91 (56) | 154 (52) |
| Managed care | 51 (38) | 49 (30) | 100 (34) |
| NC Medicaid | 13 (10) | 14 (9) | 27 (9) |
| Other | 6 (5) | 9 (6) | 15 (5) |
| Recurrent or metastatic, n (%) | |||
| Yes | 130 (98) | 159 (98) | 289 (98) |
| No | 3 (2) | 4 (2) | 7 (2) |
| Cancer type, n (%) | |||
| Bone and soft tissue | 2 (2) | 8 (5) | 10 (3) |
| Breast | 15 (11) | 19 (12) | 34 (11) |
| Colorectal | 14 (11) | 17 (10) | 31 (10) |
| Cancer of unknown primary | 8 (6) | 6(4) | 14 (5) |
| GI (noncolorectal) | 15 (11) | 10 (6) | 25 (8) |
| Genitourinary (nonprostate) | 5 (4) | 9 (6) | 14 (5) |
| Head and neck | 5 (4) | 2(1) | 7 (2) |
| Hepatobiliary | 8 (6) | 12 (7) | 20 (7) |
| Lung | 32 (24) | 34 (21) | 66 (22) |
| Melanoma | 1 (1) | 5 (3) | 6 (2) |
| Multiple | 8 (6) | 14 (9) | 22 (7) |
| Neuroendocrine | 3 (2) | 7 (4) | 10 (3) |
| Pancreatic | 14 (11) | 15 (9) | 29 (10) |
| Prostate | 3 (2) | 5 (3) | 8 (3) |